G. Villanova
About
G. Villanova is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research.
According to data from OpenAlex, G. Villanova has authored 28 papers receiving a total of 447 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 10 papers in Cancer Research. Recurrent topics in G. Villanova's work include Cancer Treatment and Pharmacology (20 papers), Advanced Breast Cancer Therapies (12 papers) and HER2/EGFR in Cancer Research (12 papers). G. Villanova is often cited by papers focused on Cancer Treatment and Pharmacology (20 papers), Advanced Breast Cancer Therapies (12 papers) and HER2/EGFR in Cancer Research (12 papers). G. Villanova collaborates with scholars based in France, Italy and Spain. G. Villanova's co-authors include C. Serradeil‐Le Gal, G. Le Fur, Corinne Garcia, Jean Wagnon, B. Christophe, P. Guiraudou, C Lacour, J.P. Maffrand, Dino Nisato and Arlene Chan and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Cancer Research.
In The Last Decade
G. Villanova
27 papers receiving 414 citations
Peers
G. Villanova
Cinthia V. Pastuskovas United States
G. V. Shah United States
Darcy L. Thull United States
Jens Rüter United States
Rick Hermsen Netherlands
Adrian Anghel United States
Vickram Bissonauth Canada
Noriko Mutsuga United States
Xiaoxiao Li China
James E. Browning United States
Citations per year, relative to G. Villanova G. Villanova (= 1×)
peers
Cinthia V. Pastuskovas
Countries citing papers authored by G. Villanova
Since
Specialization
Citations
This map shows the geographic impact of G. Villanova's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Villanova with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Villanova more than expected).
Fields of papers citing papers by G. Villanova
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by G. Villanova. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Villanova. The network helps show where G. Villanova may publish in the future.
Co-authorship network of co-authors of G. Villanova
This figure shows the co-authorship network connecting the top 25 collaborators of G. Villanova. A scholar is included among the top collaborators of G. Villanova based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Villanova. G. Villanova is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Freyer, Gilles, Noelia Martínez-Jáñez, Bożena Kukiełka-Budny, et al.. (2024). Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study. The Breast. 74. 103681–103681.
2.
Aapro, Matti, Manuel Ruíz‐Borrego, Roberto Hegg, et al.. (2019). Randomized phase II study evaluating weekly oral vinorelbine versus weekly paclitaxel in estrogen receptor-positive, HER2-negative patients with advanced breast cancer (NorBreast-231 trial). The Breast. 45. 7–14.
3.
Steger, Guenther G., Francesco Giotta, N. Tubiana-Mathieu, et al.. (2017). Single-Agent Oral Vinorelbine as First-Line Chemotherapy for Endocrine-Pretreated Breast Cancer With Bone Metastases and No Visceral Involvement: NORBREAST-228 Phase II Study. Clinical Breast Cancer. 18(1). e41–e47.
4.
Cinieri, Saverio, Arlene Chan, Kadri Altundağ, et al.. (2016). Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer. Clinical Breast Cancer. 17(2). 91–99.e1.
5.
Cinieri, Saverio, Arlene Chan, Kadri Altundağ, et al.. (2014). Three-arm randomized phase II study evaluating oral vinorelbine plus capecitabine versus paclitaxel plus gemcitabine versus docetaxel plus gemcitabine as first-line chemotherapy in patients with metastatic breast cancer: Final results (NorCap-CA223 trial).. Journal of Clinical Oncology. 32(15_suppl). 1044–1044.
6.
Steger, G.G., O. Switsers, Francesco Giotta, et al.. (2014). Phase Ii Study Evaluating Oral Vinorelbine As a Single-Agent As First-Line Chemotherapy for Metastatic Breast Cancer Patients with Bone Metastases (Norbreast-228 Trial): First Efficacy Results. Annals of Oncology. 25. iv132–iv132.
7.
Chan, Arlene, Pierfranco Conté, Luboš Petruželka, et al.. (2013). Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer.. PubMed. 33(6). 2657–64.
8.
Petruželka, Luboš, Vinod Ganju, D. Becquart, et al.. (2010). Phase II study of the combination of oral vinorelbine (NVBo), capecitabine (X), and trastuzumab (H) in HER2-positive, metastatic breast cancer (MBC): Recent analysis of the results with a median follow-up of 44 months.. Journal of Clinical Oncology. 28(15_suppl). 1077–1077.
9.
Tubiana-Mathieu, N., Philippe Bougnoux, D. Becquart, et al.. (2009). All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial. British Journal of Cancer. 101(2). 232–237.
10.
Ganju, Vinod, D. Becquart, Pierfranco Conté, et al.. (2009). 5055 High efficacy of the combination of oral vinorelbine (NVBo), capecitabine (X) and trastuzumab (H) in HER2-positive metastatic breast cancer (MBC): updated results of an international phase II trial with a median follow-up of 39 months. European Journal of Cancer Supplements. 7(2). 277–277.
11.
Tubiana-Mathieu, N., D. Becquart, A Chan, et al.. (2009). All-oral combination of oral vinorelbine (NVBo) and capecitabine (X) in HER2-negative metastatic breast cancer (MBC): latest results of a multicenter, international phase II trial with a median follow-up of 37.7 months.. Cancer Research. 69(2_Supplement). 6125–6125.
12.
Chan, A, Vinod Ganju, D. Becquart, et al.. (2008). First-line trastuzumab (H), oral vinorelbine (NVBo) and capecitabine (X) combination therapy for HER2-positive metastatic breast cancer (MBC): efficacy and safety in a multinational phase II study. European Journal of Cancer Supplements. 6(7). 220–221.
13.
Tubiana-Mathieu, N., Philippe Bougnoux, D. Becquart, et al.. (2008). All-oral vinorelbine (NVBo) and capecitabine (X) combination for chemotherapy-naive HER2-negative metastatic breast cancer (MBC) patients: efficacy and safety in an international phase II study. European Journal of Cancer Supplements. 6(7). 173–173.
14.
Tubiana-Mathieu, N., Philippe Bougnoux, D. Becquart, et al.. (2007). An international phase II study of an all-oral combination of oral vinorelbine (NVBo) and capecitabine (X) in HER2-negative metastatic breast cancer (MBC). Journal of Clinical Oncology. 25(18_suppl). 1056–1056.
15.
Chan, Arlene, Vinod Ganju, D. Becquart, et al.. (2007). Efficacy of oral vinorelbine (NVBo), capecitabine (X) and trastuzumab (H) triple combination (NVBoXH) in HER2-positive metastatic breast cancer (MBC): First results of an international phase II trial. Journal of Clinical Oncology. 25(18_suppl). 1052–1052.
16.
Chan, Arlene, Michael Untch, Marta Gil, et al.. (2006). Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial. British Journal of Cancer. 95(7). 788–793.
17.
Gal, C. Serradeil‐Le, G. Villanova, Michel Boutin, JP Maffrand, & G. Le Fur. (1995). Effects of SR 49059, a non‐peptide antagonist of vasopressin V1areceptors, on vasopressin‐induced coronary vasoconstriction in conscious rabbits. Fundamental and Clinical Pharmacology. 9(1). 17–24.
18.
Gal, C. Serradeil‐Le, Jean Wagnon, Corinne Garcia, et al.. (1993). Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors.. Journal of Clinical Investigation. 92(1). 224–231.
19.
Delhon, André, et al.. (1983). [Anti-edematous action of a hexane extract of the stone fruit of Serenoa repens Bartr].. PubMed. 41(6). 559–70.
20.
Miziak, Barbara, et al.. (1982). Modification of two models of Arthus reaction in the rat by various drugs.. PubMed. 32(1). 45–9.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Cinthia V. Pastuskovas Breakdown of academic impact, for papers by G. V. Shah Breakdown of academic impact, for papers by Darcy L. Thull Breakdown of academic impact, for papers by Jens Rüter Breakdown of academic impact, for papers by Rick Hermsen Breakdown of academic impact, for papers by Adrian Anghel Breakdown of academic impact, for papers by Vickram Bissonauth Breakdown of academic impact, for papers by Noriko Mutsuga Breakdown of academic impact, for papers by Xiaoxiao Li Breakdown of academic impact, for papers by James E. Browning